Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2024-02-14 3:01 pm Sale |
2023-12-31 | 13G | Constellation Pharmaceuticals, Inc. CNST |
Cormorant Asset Management LP | 0 0.000% |
-5,150,000![]() (Position Closed) |
Filing History |
2024-02-14 3:01 pm Sale |
2023-12-31 | 13G | Cabaletta Bio, Inc. CABA |
Cormorant Asset Management LP | 0 0.000% |
-1,971,739![]() (Position Closed) |
Filing History |
2024-02-14 3:00 pm Sale |
2023-12-31 | 13G | Astria Therapeutics, Inc. ATXS |
Cormorant Asset Management LP | 0 0.000% |
-1,650,000![]() (Position Closed) |
Filing History |
2024-02-14 3:00 pm Sale |
2023-12-19 | 13G | 89bio, Inc. ETNB |
Cormorant Asset Management LP | 0 0.000% |
-2,550,000![]() (Position Closed) |
Filing History |
2024-01-30 4:41 pm Sale |
2023-11-29 | 13D | Erasca, Inc. ERAS |
Cormorant Asset Management LP | 0 0.000% |
-10,893,107![]() (Position Closed) |
Filing History |
2023-12-14 4:04 pm Purchase |
2023-12-04 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
Cormorant Asset Management LP | 6,038,235 12.360% |
6,038,235![]() (New Position) |
Filing History |
2023-11-16 4:02 pm Purchase |
2023-11-06 | 13G | Korro Bio, Inc. KRRO |
Cormorant Asset Management LP | 679,170 8.490% |
679,170![]() (New Position) |
Filing History |
2023-11-13 4:03 pm Purchase |
2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE |
Cormorant Asset Management LP | 1,394,336 9.990% |
1,394,336![]() (New Position) |
Filing History |
2023-11-06 4:01 pm Purchase |
2023-10-25 | 13G | Harpoon Therapeutics, Inc. HARP |
Cormorant Asset Management LP | 1,678,619 9.900% |
1,678,619![]() (New Position) |
Filing History |
2023-10-23 4:02 pm Purchase |
2023-10-11 | 13G | Alpine Immune Sciences, Inc. ALPN |
Cormorant Asset Management LP | 2,850,000 5.790% |
2,850,000![]() (New Position) |
Filing History |
2023-10-13 4:00 pm Purchase |
2023-10-03 | 13G | ALX Oncology Holdings Inc. ALXO |
Cormorant Asset Management LP | 3,142,079 6.310% |
3,142,079![]() (New Position) |
Filing History |
2023-10-10 4:01 pm Purchase |
2023-09-29 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
Cormorant Asset Management LP | 2,800,000 5.530% |
2,800,000![]() (New Position) |
Filing History |
2023-04-24 5:26 pm Purchase |
2023-04-20 | 13G | Immuneering Corporation IMRX |
Cormorant Asset Management LP | 4,204,364 14.420% |
1,918,183![]() (+83.90%) |
Filing History |
2023-03-13 4:00 pm Purchase |
2023-03-03 | 13G | Ambrx Biopharma Inc. AMAM |
Cormorant Asset Management LP | 52,500,000 17.730% |
36,145,298![]() (+221.01%) |
Filing History |
2023-02-14 3:15 pm Sale |
2022-12-31 | 13G | Elevation Oncology, Inc. ELEV |
Cormorant Asset Management LP | 1,952,032 8.380% |
-31,136![]() (-1.57%) |
Filing History |
2023-02-14 3:14 pm Sale |
2022-12-31 | 13G | Constellation Pharmaceuticals, Inc. CNST |
Cormorant Asset Management LP | 5,150,000 9.210% |
-290,451![]() (-5.34%) |
Filing History |
2023-02-14 3:13 pm Sale |
2022-12-31 | 13G | GreenLight Biosciences Holdings GRNA |
Cormorant Asset Management LP | 9,188,659 6.060% |
-290,399![]() (-3.06%) |
Filing History |
2023-02-14 3:13 pm Purchase |
2022-12-31 | 13G | Immuneering Corporation IMRX |
Cormorant Asset Management LP | 2,286,181 8.660% |
33,553![]() (+1.49%) |
Filing History |
2023-02-14 3:12 pm Sale |
2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
Cormorant Asset Management LP | 16,354,702 6.050% |
-911,442![]() (-5.28%) |
Filing History |
2023-02-14 3:11 pm Sale |
2022-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
Cormorant Asset Management LP | 2,893,717 5.980% |
-108,483![]() (-3.61%) |
Filing History |